Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.

ABSTRACT:

Aims

The objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.

Methods

To evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was utilized to detect potential signals of AEs. Stratified analysis was conducted to examine the differences in AEs occurring among different genders and age groups taking pralsetinib and selpercatinib.

Results

FAERS received 891 reports for pralsetinib and 569 reports for selpercatinib. Our analysis confirmed expected AEs like hypertension, fatigue, and elevated transaminase levels. Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was l

SUBMITTER: Jie Q 

PROVIDER: S-EPMC11449734 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature